Larimar Therapeutics, Inc. LRMR
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
1/9
Piotroski F — financial health
-12.98
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$165.7M | — | -$113.3M | $78.1M |
| 2024 | — | -$80.6M | — | -$71.3M | $171.8M |
| 2023 | — | -$36.9M | — | -$33.6M | $81.7M |
| 2022 | — | -$35.4M | — | -$27.7M | $110.9M |
| 2021 | — | -$50.6M | — | -$42.4M | $64.4M |
| 2020 | — | -$42.5M | — | -$42.3M | $89.7M |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -12.98 (distress)
- Working capital / assets 0.53
- Retained earnings / assets -2.982
- EBIT / assets -1.183
- Equity / liabilities 1.152
Source: SEC EDGAR filings · CIK 0001374690 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.